Who is sponsoring NCT06103474?

NCT06103474 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT06103474?

Interventions in NCT06103474: Lumbar Magnetic Resonance Imaging (MRI).

What condition does NCT06103474 study?

NCT06103474 studies Nocebo Effect.

Is NCT06103474 still recruiting?

NCT06103474 is currently completed. Last updated 23 January 2026.

Last reviewed 2026-01-23 · How we verify

NCT06103474: CRANE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Reporting to Alleviate the Nocebo Effect

Completed NA Last updated 23 January 2026

What this trial tests

NA trial testing Lumbar Magnetic Resonance Imaging (MRI) in Nocebo Effect in 18 participants. Completed in 11 November 2025.

Timeline

14 January 2024

Primary endpoint
11 November 2025

11 November 2025

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	18
Start date	14 January 2024
Primary completion	11 November 2025
Estimated completion	11 November 2025
Sites	1 location across United States

Drugs / interventions tested

Lumbar Magnetic Resonance Imaging (MRI)

Conditions studied

Nocebo Effect — all drugs for Nocebo Effect →

Sponsor

University of Alabama at Birmingham

Who can join

18 and older, any sex, with Nocebo Effect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Terminology in radiology reports may cause patients harm by anchoring to or justifying a particular diagnosis. This phenomenon is known as the nocebo effect. MRI may cause patients to pursue more invasive procedures with little added benefit. This study aims to reproduce a study to determine the impact of clinical reporting on patient care and outcomes for those suffering from lower back pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06103474 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 23 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06103474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing